Calliditas Therapeutics AB American Depositary Shares
CALT
CALT was delisted on the 20th of September, 2024.
18 hedge funds and large institutions have $15.2M invested in Calliditas Therapeutics AB American Depositary Shares in 2022 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 3 closing their positions.
704% more call options, than puts
Call options by funds: $804K | Put options by funds: $100K
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
14% more capital invested
Capital invested by funds: $13.4M → $15.2M (+$1.81M)
13% more funds holding
Funds holding: 16 → 18 (+2)
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HSA
HBK Sorce Advisory
Erie,
Pennsylvania
|
+$726K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$12.3K |
| 3 |
Morgan Stanley
New York
|
+$4.92K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$3.35K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$3.06K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$191K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$51K |
| 3 |
IIM
Ironwood Investment Management
Boston,
Massachusetts
|
-$39.2K |
| 4 |
Optiver Holding
Amsterdam,
Netherlands
|
-$23.9K |
| 5 |
CG
Cutler Group
San Francisco,
California
|
-$3K |
CALT Hedge Fund Activity: Q4 2022 in Review
18 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Calliditas Therapeutics AB American Depositary Shares (CALT) for Q4 2022, worth a combined $15.2M — up 14% from $13.4M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new CALT positions and 3 closed out — a net gain of 2 holders — while 3 added to existing stakes and 4 trimmed.
The largest buyer was HBK Sorce Advisory, adding an estimated $726K. The largest seller was Jane Street, exiting entirely with an estimated $191K sold.
- 18 institutional investors held Calliditas Therapeutics AB American Depositary Shares (CALT) as of Q4 2022, up from 16 in Q3 2022.
- Funds reported $15.2M of Calliditas Therapeutics AB American Depositary Shares stock for Q4 2022, up 14% quarter-over-quarter.
- 5 funds opened new Calliditas Therapeutics AB American Depositary Shares positions in Q4 2022 and 3 closed out, a net change of +2 holders.
- The largest Calliditas Therapeutics AB American Depositary Shares buyer in Q4 2022 was HBK Sorce Advisory, an estimated $726K added.
- The largest Calliditas Therapeutics AB American Depositary Shares seller in Q4 2022 was Jane Street, an estimated $191K sold.
Based on aggregated 13F filings for Q4 2022.